Collaborations & Alliances

Merus, Simcere Enter Bispecific Antibodies Alliance

To develop and commercialize three bispecific antibodies in China using Merus’ Biclonics technology platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merus has granted Simcere Pharmaceutical Group an exclusive license to develop and commercialize three bispecific antibodies in China using Merus’ Biclonics technology platform in the area of immuno-oncology. Merus will retain all rights outside of China.  Merus will lead research and discovery activities and Simcere will be responsible for the Investigational New Drug (IND) enabling studies, clinical development, regulatory filings and commercialization of these products in China. Also, Simc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters